Answers are grounded in this paper and cite their sources.
Background: The development of a licensed malaria vaccine has been challenging due to the complex multi-stage life cycle, antigenic variation, and genetic diversity of Plasmodium. Numerous vaccines have been developed for various stages of Plasmodium, including pre-erythrocytic, blood stage, placenta, and transmission-blocking vaccines. However, none of these vaccines are completely effective and have high reactogenicity.Aim: The aim of this review is to examine the challenges and prospects in developing an effective malaria vaccine, with a focus on the development of a multi-stage or multivalent malaria vaccine.Materials and Methods: The authors conducted a review of the literature on malaria vaccine development, focusing on the challenges and prospects of developing an effective malaria vaccine.Results: Efforts are underway to develop a multi-stage or multivalent malaria vaccine (MultiMalVax) that may best target sporozoite development and neutralize merozoites, hepatocytes, and erythrocytes. A thorough understanding of potential vaccine targets and how immunity works is critical to developing a fully effective malaria vaccine.Conclusion: The challenges associated with developing an effective malaria vaccine are significant due to the complex nature of the Plasmodium life cycle. However, the development of a multi-stage or multivalent malaria vaccine offers prospects for overcoming these challenges and developing a fully effective malaria vaccine. A better understanding of potential vaccine targets and how immunity works is crucial in developing an effective vaccine against malaria.
No takes yet. Share an insight, caveat, or question.
Etefia et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: